- Specialty Pharmacy List
- CAP Patient Enrollment
- Full Prescribing Information
- Prescribing Information en Español
CAYSTON may help you breathe better
CAYSTON was studied in a clinical trial with 164 patients with CF and Pa lung infection who were 7 years of age and older, with an FEV1 of 25% to 75% predicted. Patients were not on antibiotics for at least 28 days before starting the study. During the study, 80 patients received CAYSTON and 84 patients received placebo (a salt solution with no medication in it) 3 times a day for 28 days by inhalation with the Altera® Nebulizer System. Patients used an inhaled bronchodilator (a medicine used to relax and open your airways) prior to taking CAYSTON or placebo.7
The study looked at the effect of CAYSTON compared to placebo on:
- Breathing symptoms, such as coughing, wheezing, and sputum production. Changes in respiratory symptoms were assessed using a questionnaire that asks patients to report on symptoms like coughing, wheezing, and sputum production.
- Lung function, as measured by FEV1 (L)
CAYSTON provided results that patients felt through improved breathing symptoms such as coughing, wheezing, and mucus production.
In the clinical study, patients with CF and Pa who used CAYSTON reported statistically significant improvement vs placebo in breathing symptoms like coughing, wheezing, and mucus production on Day 28.
Improvements in breathing symptoms were seen in both adult and pediatric patients but were smaller in adult patients.
Two weeks after completion of treatment, patients treated with CAYSTON still had improved breathing symptoms compared to those who took placebo. However, the difference was smaller.
Click here for a list of common side effects.
“I really noticed a difference in my respiratory symptoms after 28 days on CAYSTON… when I'm on CAYSTON, I don't wheeze or cough up as much sputum.”
– KC, age 19
(Individual results may vary.)